MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar
February 15 2023 - 3:30PM
MDxHealth Announces Update of Outstanding Shares and Voting Rights
and Update of Financial Calendar
NEWS RELEASE – REGULATED
INFORMATIONFEBRUARY
15, 2023,
4:30
pm ET/
22:30
CET
IRVINE, CA, and HERSTAL,
BELGIUM – February 15, 2023 – MDxHealth SA
(NASDAQ/Euronext: MDXH) (“mdxhealth” or the
“Company“), a commercial-stage precision
diagnostics company, today announced, in accordance with Article 15
of the Belgian Act of May 2, 2007 on the disclosure of major
participations in issuers of which shares are admitted to trading
on a regulated market and regarding miscellaneous provisions, that
in the context of the capital increase that was announced on
February 1, 2023 and completed on February 7, 2023, its share
capital has increased from EUR 123,539,165.19 to
EUR 160,658,690.06, and the number of issued and outstanding
shares has increased from 162,880,936 to 262,880,936 ordinary
shares, through the issuance of a total of 100,000,000 new
shares.
In addition to the outstanding shares of the Company:
- a total of
13,895,280 subscription rights of the Company is outstanding, which
entitles their holders (assuming all subscription rights are
granted and exercised) to subscribe to a total of 13,895,280 new
shares with voting rights;
- under the loan
agreement entered into by the Company and Kreos Capital in
July 2021, a drawdown fee equal to 7% of the amounts drawn
down under the loan agreement (being EUR 630,000 in aggregate)
remains outstanding as a payable due by the Company (without
accruing interest), and is convertible into ordinary shares with
voting rights by means of a contribution in kind of the payable by
Kreos Capital to the share capital of the Company at a price of EUR
0.85 per share; and
- under the loan
and security agreement entered into by the Company and Innovatus
Capital Partners in August 2022, Innovatus has the right to
convert, prior to August 2, 2025, up to 15% of the outstanding
principal amount of the loans (by means of a contribution in kind
of the relevant payables due by the Company under the loans) into
American Depositary Shares ("ADSs") of the Company
(each representing 10 ordinary shares of the Company) at a
conversion price per ADS equal to USD 11.21 (i.e.,
USD 1.121 per share on the basis of the ratio of 1 ADS per 10
shares).
Update of the 2023 Reporting Calendar
In addition, the Company announces that its financial calendar
for 2023 shall be as follows:
- March 8, 2023: 2022 FY results
- May 10, 2023: Q1-2023 business update
- May 25, 2023: Annual general shareholders' meeting
- August 23, 2023: Publication of H1-2023 results
- November 8, 2023: Q3-2023 business update
About mdxhealth®
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
For more
information:mdxhealthinfo@mdxhealth.com
LifeSci Advisors (IR &
PR)US: +1 949 271 9223ir@mdxhealth.com
NOTE: The mdxhealth logo, mdxhealth, Confirm
mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and
Monitor mdx are trademarks or registered trademarks of MDxHealth
SA. All other trademarks and service marks are the property of
their respective owners.
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Jan 2025 to Feb 2025
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Feb 2024 to Feb 2025
